Natco Pharma Ltd (BOM:524816)

Q3 2026 Natco Pharma Ltd Earnings Call Transcript

Feb 12, 2026 / 10:30AM GMT

Release Date Price: ₹839.9 (-1.28%)

Transcript

Key Points

Positve

Natco Pharma Ltd (BOM:524816) reported a consolidated total revenue of INR705.4 crore for Q3 FY26, up from INR651.1 crore in the same period last year.
The company achieved an EBITDA of INR216.8 crore with a margin of 30.7%, indicating strong operational efficiency.
Natco Pharma Ltd declared an interim dividend of INR1.5 per equity share, reflecting a commitment to returning value to shareholders.
The company is actively pursuing acquisitions and has a strong cash position of INR2,500 crore, which it plans to use for future transactions.
Natco Pharma Ltd's strategy of expanding into emerging markets has paid off, with significant contributions from Brazil, Canada, and the Middle East.

Negative

The company has no current capacity for GLP-1 production and is outsourcing from a single source, which may limit scalability.
There is no immediate plan for a share buyback despite favorable valuations, as the company prioritizes cash preservation for acquisitions.
The domestic semaglutide market is expected to be highly competitive with multiple generics, which could impact market share and pricing.
Natco Pharma Ltd's revenue growth is heavily reliant on the success of semaglutide, which introduces risk if market conditions change.
The company has not budgeted for significant Revlimid revenue in the current quarter, indicating potential volatility in earnings.

Operator

Ladies and gentlemen, good day, and welcome to the NATCO Pharma's Q3 and FY26 Earnings Conference Call hosted by Batlivala & Karani Securities India Private Limited. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Hrishikesh Patole from Batlivala & Karani Securities. Thank you, and over to you, sir.

Hrishikesh Patole;Rajesh Chebiyam

Batlivala & Karani Securities India Pvt Ltd - Research Analyst;Natco Pharma Ltd - Executive Vice President - Crop

Hello. Thank you. Good afternoon, everyone. On behalf of B&K Securities, I welcome you all to the Q3 FY26 Earnings Conference Call of NATCO Pharma. Hope everyone is in good health and doing well. On behalf of NATCO today, we have with us Mr. Rajeev Nannapaneni, Vice Chairman and CEO; Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences.

I now hand over the call to Rajesh for the management's opening remarks, post which we'll open the session for Q&A. Over to you, Rajesh.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.